Related Experiment Video
Updated: Jul 20, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.2K
Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer
Shayan Smani1, Julien DuBois1, Kai Zhao1
1Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA.
Current Oncology Reports
|February 20, 2025
Summary
Managing non-muscle invasive bladder cancer (NMIBC) is evolving with new biomarkers and immunotherapies. Risk stratification guides treatment to balance efficacy and reduce overtreatment for better patient outcomes.
Area of Science:
- Oncology
- Urology
Background:
- Non-muscle invasive bladder cancer (NMIBC) management requires careful risk assessment.
- Current treatment strategies balance recurrence and progression risks.
Purpose of the Study:
- To review the evolving landscape of NMIBC management.
- Focus on risk stratification, novel therapies, and biomarker integration.
Main Methods:
- Literature review of recent advancements in NMIBC.
- Analysis of current guidelines and emerging therapeutic strategies.
Main Results:
- Genomic markers (FGFR3, TERT) show diagnostic and personalized treatment potential.
- Immunotherapies (pembrolizumab, nadofaragene firadenovec) offer options for BCG-unresponsive NMIBC.
- Risk-stratified care and early radical cystectomy for high-risk cases are emphasized.
Conclusions:
- Biomarker-driven models are crucial for refining NMIBC treatment paradigms.
- Reducing overtreatment and improving long-term outcomes are key goals.
- Further clinical trials are needed to validate new approaches for NMIBC care.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.